𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Pegylated (40 kDa) interferon alfa-2a (PEGASYS®) in combination with ribavirin, mycophenolate mofetil (CellCept®), amantadine, or amantadine plus ribavirin in patients that did not respond to rebetronTM therapy: A preliminary report of a randomized, multicenter study

✍ Scribed by Afdhal, Nezam; Flamm, Steven; Imperial, Joanne; Malet, Peter F.; Tong, Myron; Campagna, Jennifer; Pappas, Stephen C.

Book ID
124103532
Publisher
Elsevier Science
Year
2001
Tongue
English
Weight
157 KB
Volume
120
Category
Article
ISSN
0016-5085

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Analyses of 40 kDa peginterferon alfa-2A
Analyses of 40 kDa peginterferon alfa-2A (Pegasys®) in combination with ribavirin, mycophenolate mofetil, amantadine, or amantadine plus ribavirin in patients that relapsed or did not respond to rebetron™ therapy: a report of two randomized, multicenter, efficacy and safety studies: Nezam Afdhal, Beth Israel Deaconess Medical Ctr, Boston, MA; Steven Flamm, Northwestern Memorial Hospital, Chicago, IL; Joanne C Imperial, Stanford University School of Medicine, Palo Alto, CA; Peter F Malet, University of Texas Southwestern Medical Center, Dallas, TX; Myron Tong, Hungtington Hospital Liver Center, Pasadena, CA; Steven K Herrine, Thomas Jefferson University Hospital, Philadelphia, PA; Robert Brown Jr., Columbia Presbyterian Medical Center, New York, NY; Stephen Esposito, Hepatobiliary Associates of New York, Bayside, NY; David E Bernstein, North Shore University Hospital, Manhasset, NY; Jennifer L Campagna, Roche Laboratories Inc, Nutley, NJ
📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 235 KB